ÂÜẠ̀ẨÂ×

John McDermott joined Vascular Therapies as of January 2019 as Chief Executive Officer. Mr. McDermott has over 30 years of senior executive management, sales, marketing, and finance experience in the vascular industry. From 2008 to 2018 he served as the CEO of Endologix, a public company that is a developer of aortic stent grafts. From 2002 to 2007 he served as President of Bard Peripheral Vascular, a division of C.R. Bard, Inc. Mr. McDermott previously served as President of Global Sales for C.R. Bard’s vascular surgery and endovascular businesses.

Prior to that, he served for four years as President of C.R. Bard’s division IMPRA, Inc., where he was responsible for global operations, including sales, marketing, research and development, manufacturing, and finance. From 1990 to 1996, Mr. McDermott served as Chief Financial Officer and later Vice President and Chief Operating Officer of IMPRA, Inc., prior to its acquisition by C.R. Bard.

Mr. McDermott holds a B.S. in Finance from Arizona State University and an M.B.A from Western International University.